The year in charts

The year in charts

Tuesday, April 25, 2023 @ 7:00 am

Capital investments in Swiss biotech companies 2012-2022

Revenues, R&D expenses, profit/loss, liquidity 2020-2022

Total Swiss Biotech Companies

Revenues, R&D expenses, profit/loss, liquidity 2020-2022 — Note: The 2022 data in above tables is based on information that was available up until March 31, 2023. At this time, some of the companies had not yet disclosed
their financial figures for 2022. Therefore some figures were carefully extrapolated on the basis of the latest interim data publicly available (i.e. Q3 or Q4 2022).

Revenues, R&D expenses, profit/loss, liquidity 2020-2022

Public Swiss Biotech Companies

Revenues, R&D expenses, profit/loss, liquidity 2020-2022

Private Swiss Biotech Companies

Number of biotech companies in Switzerland 2013-2022

Number of employees in Swiss R&D biotech companies 2020-2022

Tags

You may also be interested in

Beware of fraudulent emails impersonating the Swiss Biotech Association

Don’t fall for fraudsters! Cyber criminals can reach you easily with today's communication means. We regularly detect fraudulent emails attempting to steal your passwords — both personal and for our systems — through phishing attacks. Smishing (SMS, text messages) or vishing (phone calls) are also a common way to retrieve information from you. With seemingly legitimate messages the criminals
October 8, 2024

InSphero and PharmaNest: Partnership to advance translational fibrosis research

InSphero AG, the global market leader in 3D cell-based assays and organ-on-chip systems signed a partnership with PharmaNest Inc, a Princeton, NJ-based digital pathology company.
February 11, 2026

Industry leaders form alliance for microphysiological systems

A new united voice for a strategic sector for Europe
February 10, 2026

Akceso Advisors elects Seng Chin Mah as board member

Akceso Advisors AG, a leading independent global advisory firm specializing in market access, pricing, reimbursement strategy, operations and policy-setting for life-science companies and authorities, announced today the election of Dr. Seng Chin Mah as a new non-executive member of its Board of Directors.
February 10, 2026

abc biopply: New organoid competence center in Basel

abc biopply announces today the opening of its new Organoid Competence Center at the Swiss Innovation Park Basel. With this new location, the company expands its portfolio of highly standardized and fully integrated Organoid CRO services and brings them for the first time to Basel — one of the world’s leading hubs for drug discovery and development.
February 5, 2026

Cosmo: Substantial private placement with Capital Group

February 3, 2026